Cystic Fibrosis–Associated Liver Disease in Lung Transplant Recipients
暂无分享,去创建一个
[1] M. Stanbrook,et al. VX-659–Tezacaftor–Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles , 2020, Canadian Journal of Respiratory, Critical Care, and Sleep Medicine.
[2] T. Alexopoulos,et al. Evaluation of noninvasive markers for the diagnosis of cystic fibrosis liver disease , 2018, Scandinavian journal of gastroenterology.
[3] F. van Goor,et al. VX‐445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles , 2018, The New England journal of medicine.
[4] B. Meiser,et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth adult lung and heart-lung transplant report-2018; Focus theme: Multiorgan Transplantation. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[5] A. Ba-Ssalamah,et al. The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study , 2018, European Radiology.
[6] F. Lehner,et al. The liver-first approach for combined lung and liver transplantation , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[7] S. Davison. Assessment of liver disease in cystic fibrosis. , 2018, Paediatric respiratory reviews.
[8] C. Koh,et al. Liver disease in patients with cystic fibrosis , 2018, Current opinion in gastroenterology.
[9] S. Knechtle,et al. Single-Center Long-Term Analysis of Combined Liver-Lung Transplant Outcomes , 2018, Transplantation direct.
[10] Sherie J Smith,et al. Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. , 2018, The Cochrane database of systematic reviews.
[11] M. Guill,et al. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis , 2018, Annals of the American Thoracic Society.
[12] J. Pilewski,et al. Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[13] H. Grasemann. CFTR Modulator Therapy for Cystic Fibrosis. , 2017, The New England journal of medicine.
[14] G. Snell,et al. The evolution of lung transplantation for cystic fibrosis: A 2017 update. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[15] J. Hoofnagle,et al. Adult‐onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity , 2017, Hepatology.
[16] E. Roeb,et al. Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: Results from a prospective longitudinal cohort study , 2017, PloS one.
[17] G. Casazza,et al. Platelet count, spleen length, and platelet count-to-spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis. , 2017, The Cochrane database of systematic reviews.
[18] M. Davenport,et al. King's Variceal Prediction Score: A Novel Noninvasive Marker of Portal Hypertension in Pediatric Chronic Liver Disease , 2017, Journal of pediatric gastroenterology and nutrition.
[19] R. Houwen,et al. Current and future therapies for inherited cholestatic liver diseases , 2017, World journal of gastroenterology.
[20] S. McColley,et al. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del‐CFTR , 2017, Annals of the American Thoracic Society.
[21] J. Bosch,et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases , 2017, Hepatology.
[22] R. Houwen,et al. Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[23] K. Setchell,et al. Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease. , 2016, The Journal of pediatrics.
[24] D. Waltz,et al. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. , 2016, The Lancet. Respiratory medicine.
[25] A. Geerts,et al. Longitudinal Transient Elastography Measurements Used in Follow-up for Patients with Cystic Fibrosis. , 2016, Ultrasound in medicine & biology.
[26] M. Egan. Genetics of Cystic Fibrosis: Clinical Implications. , 2016, Clinics in chest medicine.
[27] E. Kerem,et al. Hepatopulmonary Syndrome in Patients With Cystic Fibrosis and Liver Disease. , 2016, Chest.
[28] G. Tomlinson,et al. Effects of Recipient Age and Diagnosis on Health-related Quality-of-Life Benefit of Lung Transplantation. , 2015, American journal of respiratory and critical care medicine.
[29] Xiaohong Huang,et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.
[30] G. A. Whitmore,et al. A contemporary survival analysis of individuals with cystic fibrosis: a cohort study , 2014, European Respiratory Journal.
[31] V. Ng,et al. Simultaneous liver-pancreas transplantation for cystic fibrosis-related liver disease: a multicenter experience. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[32] M. Narkewicz,et al. Cirrhosis and other liver disease in cystic fibrosis. , 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[33] T. Remmington,et al. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. , 2013, Paediatric respiratory reviews.
[34] Melissa R. Miller,et al. Pulmonary function in individuals who underwent liver transplantation: From the US cystic fibrosis foundation registry , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[35] J. Hodson,et al. Long‐Term Impact of Liver Transplantation on Respiratory Function and Nutritional Status in Children and Adults With Cystic Fibrosis , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[36] P. Burgel,et al. Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation. , 2011, Journal of hepatology.
[37] B. Strandvik,et al. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[38] J. Pilewski,et al. Does simultaneous lung-liver transplantation provide an immunologic advantage compared with isolated lung transplantation? , 2011, The Journal of thoracic and cardiovascular surgery.
[39] K. Reddy,et al. Liver transplantation in patients with cystic fibrosis: Analysis of united network for organ sharing data , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[40] J. Gustafson,et al. Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.
[41] M. Corey,et al. Genetic modifiers of liver disease in cystic fibrosis. , 2009, JAMA.
[42] F. Algar,et al. Results of lung transplantation in patients with cystic fibrosis. , 2008, Transplantation proceedings.
[43] C. Goss,et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. , 2007, American journal of respiratory and critical care medicine.
[44] S. Gandhi,et al. Lower Incidence of Bronchiolitis Obliterans in Pediatric Liver−Lung Transplant Recipients With Cystic Fibrosis , 2007, Transplantation.
[45] A. Befeler,et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis , 2007, Current gastroenterology reports.
[46] A. Morabito,et al. Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome , 2002, Hepatology.
[47] R. Calne. Immunological tolerance: the liver effect , 2002, Immunological reviews.
[48] B. Strandvik,et al. Natural history of liver disease in cystic fibrosis , 1999, Hepatology.
[49] R. Kotloff,et al. Lung transplantation for cystic fibrosis. , 1998, Clinics in chest medicine.
[50] S. Schwarzenberg,et al. Variceal Hemorrhage and Adverse Liver Outcomes in Patients With Cystic Fibrosis Cirrhosis , 2018, Journal of pediatric gastroenterology and nutrition.
[51] D. Al-Adra,et al. Combined lung-liver-pancreas transplantation in a recipient with cystic fibrosis. , 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[52] E. Ingenito,et al. Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del , 2017, The New England journal of medicine.
[53] R. Gruessner,et al. Survival of cystic fibrosis patients undergoing liver and liver-lung transplantations. , 2013, Transplantation proceedings.
[54] D. Ashby,et al. Ursodeoxycholic acid for cystic fibrosis-related liver disease. , 2012, The Cochrane database of systematic reviews.
[55] S. Keshavjee,et al. Outcomes of patients with cystic fibrosis undergoing lung transplantation with and without cystic fibrosis‐associated liver cirrhosis * , 2012, Clinical transplantation.
[56] K. Lindor,et al. What's Hot in the Red Journal This Month , 2011, The American Journal of Gastroenterology.